|Founded||August 2004 by merger|
|Olivier Charmeil Executive Vice President, Vaccines|
|Slogan||Because health matters. (French: L'essentiel c'est la santé.)|
In 1994, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group, changed its name to Sanofi Pasteur. In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable. Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks will run out in June 2016.
- 1897: Marcel Mérieux creates the Mérieux Biological Institute in Lyon. Richard Slee creates the Pocono Biological Laboratories, in Swiftwater, Pennsylvania in the U.S.
- 1914: John FitzGerald creates Connaught Laboratories, part of the University of Toronto.
- 1968: Rhône-Poulenc acquires 51% of the capital of the Institut Mérieux.
- 1974: Pasteur Institute creates Pasteur Production, a subsidiary specializing in manufacturing vaccines.
- 1978: Connaught Laboratories in Canada acquires the vaccine manufacturing facility (Merrell-National Laboratories) at Swiftwater, Pennsylvania, U.S.
- 1985: Pasteur Production is acquired by the Mérieux Institute, and Pasteur Vaccins is created.
- 1989: The Mérieux Institute acquires the Connaught Laboratories in Canada and its subsidiaries and becomes a world leader in human biology.
- 1990: Creation of Pasteur Mérieux Serums & Vaccins.
- 1994: Pasteur Mérieux Sérums & Vaccins becomes a wholly owned subsidiary of Rhône-Poulenc.
- 1996: Pasteur Mérieux Connaught is the new name of Pasteur Mérieux Serums et Vaccins.
- 1999: Rhône-Poulenc and Hoechst unite their Life Sciences activities in a single company, which takes on the name Aventis. Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur.
- 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur.
- 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
- 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics.
Key facts & figures in 2012
- 2012 net sales: €3,897 millions (+5.7% over 2011)
- Staff: nearly 13,000 employees worldwide
- More than 1 billion doses of vaccines produced yearly to immunize more than 500 million people in the world
- Largest product range available, against 20 infectious diseases
- More than €1 million invested every day in R&D
- Nearly €2 billion invested in the last 5 years in production infrastructures.
- Headquarters: Lyon, France
- 14 production and/or R&D sites located in:
- Marcy-l'Étoile and Val-de-Reuil, France
- Swiftwater, Pennsylvania (Sanofi Pasteur's United States headquarters), Cambridge, Massachusetts and Canton, Massachusetts, Orlando, Florida and Rockville, Maryland, United States
- Toronto, Canada
- Pilar, Buenos Aires Province, Argentina
- Shenzhen, China
- Hyderabad, India
- Ocoyoacac, Mexico
- Chachoengsao, Thailand
- Neuville-sur-Saône, France
- TheraCys - bladder cancer
- ADACEL (Tdap) - diphtheria, tetanus and pertussis
- DAPTACEL (DTaP) - diphtheria, tetanus and pertussis
- Diphtheria and Tetanus Toxoids Adsorbed USP, diphtheria, tetanus and pertussis
- Tetanus Toxoid Adsorbed - diphtheria, tetanus and pertussis
- TriHIBit (DTaP/Hib Booster Use) - diphtheria, tetanus and pertussis and haemophilus influenzae type b
- Tripedia (DTaP vaccine) - diphtheria, tetanus, pertussis
- ActHIB - haemophilus influenzae type b
- Fluzone, Influenza Virus Vaccine - influenza
- Fluzone, Influenza Virus Vaccine, No Preservative - influenza
- Fluzone, Influenza Virus Vaccine, No Preservative: Ped Dose - influenza
- Menactra - meningococcal
- In 2011, Menactra became the first meningococcal vaccine approved for use in infants.
- Menomune-A/C/Y/W-135 - meningococcal
- IPOL - Polio
- Imogam Rabies-HT - rabies immune globulin
- IMOVAX RABIES - rabies
- DECAVAC - tetanus and diphtheria
- Tetanus Toxoid Adsorbed - tetanus 
- Tetanus Toxoid For Booster Use Only - tetanus
- JE-VAX - Japanese encephalitis virus
- Typhim Vi - typhoid fever
- YF-VAX - yellow fever
- Tubersol - tuberculosis
2012 BCG supply shortage
In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. The Toronto Sanofi plant  On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.
- "Sanofi Pasteur Vaccine Hub". www.vaccinehub.com.au. Retrieved 1 March 2014.
- "sanofi-aventis : Sanofi Pasteur, the vaccine division of the Sanofi-aventis Group, changes its name to sanofi pasteur". Retrieved 2007-11-04.
- Associated Press (7 September 2015). "Snakebite anti-venom running out worldwide, MSF". CBC News. Retrieved 8 September 2015.
- "Why vaccinate?". www.vaccinehub.com.au. Retrieved 1 March 2014.
- "Connaught and the Canadian Polio Vaccine Story +". CONNTACT, June 1996 (Vol. 9 No. 3) (Employee News of Connaught Laboratories Limited). Retrieved 11 December 2012.
- "Sanofi Pasteur US Products". Retrieved 2007-12-04.
- Staff Writer (25 April 2011). "FDA Grants Licensure To Expand Indication For Sanofi Pasteur's Menactra". RTTNews. Retrieved 26 April 2011.
- "April 2012 Inspectional Observations (form 483)", U.S. Food and Drug Administration, Vaccines, Blood & Biologics, April 12, retrieved 29 January 2016 Check date values in:
- Fine, P.E.M (2004). Issues relating to the use of BCG in immunization programmes: A discussion document, WHO/V&B/99.23 (PDF). Geneva: WHO.
- Palmer, Eric (10 September 2014), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
- Palmer, Eric (12 July 2012), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
- Palmer, Eric (31 March 2015), "Sanofi Canada vax plant again producing ImmuCyst bladder cancer drug", FiercePharma, retrieved 29 January 2016